A detailed history of Kennedy Capital Management, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 10,466 shares of NTLA stock, worth $127,475. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,466
Holding current value
$127,475
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $206,389 - $286,349
10,466 New
10,466 $215,000
Q2 2022

Aug 10, 2022

SELL
$38.49 - $76.21 $128,864 - $255,151
-3,348 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $52,734 - $107,685
905 Added 37.04%
3,348 $243,000
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $21,058 - $28,917
-209 Reduced 7.88%
2,443 $289,000
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $7,280 - $9,722
-55 Reduced 2.03%
2,652 $356,000
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $164,802 - $438,290
2,707 New
2,707 $438,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.